DOCSLIB.ORG

IMPORTANT: You Must Read the Following Before Continuing. The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

IMPORTANT: You must read the following before continuing. The following applies to the prospectus following this page (the “Prospectus”), and you are therefore required to read this carefully before reading, accessing or making any other use of the Prospectus. In accessing the Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them any time you receive any information from us as a result of such access. THE FOLLOWING PROSPECTUS MAY NOT BE FORWARDED OR DISTRIBUTED OTHER THAN AS PROVIDED BELOW AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. THIS PROSPECTUS MAY ONLY BE DISTRIBUTED OUTSIDE THE UNITED STATES TO PERSONS THAT ARE NOT U.S. PERSONS AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). ANY FORWARDING, ANY OTHER DISTRIBUTION OR ANY REPRODUCTION OF THIS PROSPECTUS IN WHOLE OR IN PART IS UNAUTHORISED. FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS. NOTHING IN THIS ELECTRONIC TRANSMISSION CONSTITUTES AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS. Confirmation of your Representation: In order to be eligible to view this Prospectus or make an investment decision with respect to the securities, you must be a person other than a U.S. person (a “U.S. Person”) (within the meaning of Regulation S under the Securities Act) who is outside the United States. By accepting the email and accessing this Prospectus, you shall be deemed to have represented to us that you and any customers you represent are not a U.S. Person; the electronic mail address that you have given to us and to which this e-mail has been delivered is not located in the U.S., its territories and possessions (including Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, Wake Island and the Northern Mariana Islands), any State of the United States or the District of Columbia; and that you consent to delivery of this Prospectus by electronic transmission. You are reminded that this Prospectus has been delivered to you on the basis that you are a person into whose possession this Prospectus may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located and you may not, nor are you authorised to, deliver this Prospectus to any other person. Any materials relating to the offering do not constitute, and may not be used in connection with, an offer or solicitation in any place where offers or solicitations are not permitted by law. If a jurisdiction requires that the offering be made by a licensed broker or dealer and any underwriter or any affiliate of any underwriter is a licensed broker or dealer in that jurisdiction, any offering shall be deemed to be made by the underwriter or such affiliate on behalf of the Issuer in such jurisdiction. Under no circumstances shall this Prospectus constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction where it is unlawful to do so. PROSPECTUS DATED 19 JANUARY 2015 The Wellcome Trust Limited (incorporated in England and Wales under the Companies Acts 1985 to 1989 with registered number 2711000) €400,000,000 1.125 per cent. Bonds due 2027 Issue Price 98.681 per cent. The €400,000,000 1.125 per cent. Bonds due 2027 (the “Bonds”) will be issued by The Wellcome Trust Limited (the “Issuer”) (in its capacity as trustee of the Wellcome Trust, a charity registered with the Charity Commission for England and Wales with registered charity number 210183 (the “Wellcome Trust”)). Interest on the Bonds is payable annually in arrear on 21 January in each year. If payments on the Bonds are subject to withholding or deduction for or on account of taxes of the United Kingdom, such payments will be increased to the extent and in the circumstances described under “Terms and Conditions of the Bonds – Taxation”. The Bonds will mature on 21 January 2027 but may be redeemed before that date at the option of the Issuer (in its capacity as trustee of the Wellcome Trust) in whole but not in part at any time at a redemption price which is equal to the higher of (i) their principal amount and (ii) a price calculated by reference to the yield on the relevant German Bundesobligationen, plus 0.15 per cent., in each case, together with accrued interest. See “Terms and Conditions of the Bonds – Redemption and Purchase”. The Bonds are also subject to redemption in whole but not in part, at their principal amount, together with accrued interest, at the option of the Issuer (in its capacity as trustee of the Wellcome Trust) at any time in the event of certain changes affecting taxes of the United Kingdom. See “Terms and Conditions of the Bonds – Redemption and Purchase”. This Prospectus has been approved by the Central Bank of Ireland (the “Central Bank”), as competent authority under Directive 2003/71/EC, as amended (including the amendments made by Directive 2010/73/EU) (the “Prospectus Directive”). This Prospectus constitutes a prospectus for the purposes of the Prospectus Directive. The Central Bank only approves this Prospectus as meeting the requirements imposed under Irish and EU law pursuant to the Prospectus Directive. Application has been made to The Irish Stock Exchange Plc (the “Irish Stock Exchange”) for the Bonds to be admitted to its official list (the “Official List”) and trading on the Main Securities Market of the Irish Stock Exchange (the “Market”). References in this Prospectus to Bonds being “listed” (and all related references) shall mean that the Bonds have been admitted to trading on the Market and have been admitted to the Official List. The Market is a regulated market for the purposes of Directive 2004/39/EC of the European Parliament and of the Council on markets in financial instruments. The Bonds will initially be represented by a temporary global bond (the “Temporary Global Bond”), without interest coupons, which will be issued in new global note (“NGN”) form as they are intended to be eligible collateral for Eurosystem monetary policy. The Temporary Global Bond will be delivered on or prior to 21 January 2015 to a common safekeeper (the “Common Safekeeper”) for Euroclear Bank S.A./N.V. (“Euroclear”) and Clearstream Banking, société anonyme (“Clearstream, Luxembourg”). The Temporary Global Bond will be exchangeable for interests in a permanent global bond (the “Permanent Global Bond” and together with the Temporary Global Bond, the “Global Bonds”), without interest coupons, on or after a date which is expected to be 3 March 2015 upon certification as to non-U.S. beneficial ownership. The Permanent Global Bond will be exchangeable for definitive Bonds in bearer form in the denominations of €100,000 and integral multiples of €1,000 in excess thereof, up to and including €199,000 in the limited circumstances set out in it. No definitive Bonds will be issued with a denomination above €199,000. See “Summary of Provisions relating to the Bonds while in Global Form”. The Bonds will be rated Aaa by Moody’s Investors Service Limited (“Moody’s”) and AAA by Standard & Poor’s Credit Market Services Europe Limited (“Standard & Poor’s”). A rating is not a recommendation to buy, sell or hold securities and may be subject to suspension, reduction or withdrawal at any time by the assigning rating agency. Standard & Poor’s and Moody’s are established in the EU and are registered under Regulation (EC) No. 1060/2009. The Bonds may not be offered, sold or delivered within the United States or to U.S. Persons unless the Bonds are registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or an exemption from the registration requirements under the Securities Act is available. The Bonds have not been and will not be registered under the Securities Act and are subject to U.S. tax law requirements. For a further description of certain restrictions on the offering and sale of the Bonds and on distribution of this Prospectus see "Subscription and Sale" below. Prospective investors should have regard to the factors described under the section headed “Risk Factors” in this Prospectus. This Prospectus does not describe all the risks of an investment in the Bonds. Joint Lead Managers BofA Merrill Lynch J.P. Morgan Morgan Stanley 1 This Prospectus comprises a prospectus for the purposes of the Prospectus Directive and for the purpose of giving information with regard to the Issuer (in its capacity as trustee of the Wellcome Trust), the Wellcome Trust, the Wellcome Trust and its subsidiaries taken as a whole (the “Group”) and the Bonds which according to the particular nature of the Issuer (in its capacity as trustee of the Wellcome Trust), the Wellcome Trust, the Group and the Bonds is necessary to enable investors to make an informed assessment of the assets and liabilities, financial position, profit and losses and prospects of the Issuer (in its capacity as trustee of the Wellcome Trust), the Wellcome Trust and the Group and of the rights attaching to the Bonds. The Issuer (in its capacity as trustee of the Wellcome Trust) accepts responsibility for the information contained in this Prospectus.
Recommended publications
  • Wellcome Trust Annual Report and Financial Statements 2017 Contents

    Wellcome Trust Annual Report and Financial Statements 2017 Contents

    Annual Report and Financial Statements 2017 2 Wellcome Trust Annual Report and Financial Statements 2017 Contents Report from the Chair and the Director 5 Trustee’s Report 8 What we do 8 Review of Charitable Activities 9 Review of Investment Activities 18 Financial Review 29 Structure and Governance 34 Risk Management 37 Remuneration Report 40 Audit Committee Report 43 Independent Auditor’s Report 45 Financial Statements 58 Consolidated Statement of Financial Activities 58 Consolidated Balance Sheet 59 Statement of Financial Activities of the Trust 60 Balance Sheet of the Trust 61 Consolidated Cash Flow Statement 62 Notes to the Financial Statements 63 Reference and Administrative Details 117 3 Wellcome Trust Annual Report and Financial Statements 2017 “ At Wellcome, we believe in the power of ideas to improve health” Jeremy Farrar Director 4 Wellcome Trust Annual Report and Financial Statements 2017 Report from the Chair and the Director “Our core approach is funding people to explore great ideas, at every step of the way from discovery to impact” At Wellcome, we believe in the power of ideas to improve cause of maternal mortality in the world. It also includes health. Funded from our independent investment portfolio, supporting research in the humanities and social sciences, we support thousands of scientists and researchers in more such as a project which this year published ethical guidelines than 70 countries, as well as innovators, educators and artists. for involving pregnant women in Zika vaccine research. Together, we take on big problems, fuel imaginations and spark And resources like the Human Induced Pluripotent Stem Cell debate, working always to achieve better health for everyone.
  • ANNUAL REVIEW 1 October 2005–30 September

    ANNUAL REVIEW 1 October 2005–30 September

    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
  • Ensembl Genomes: Extending Ensembl Across the Taxonomic Space P

    Ensembl Genomes: Extending Ensembl Across the Taxonomic Space P

    Published online 1 November 2009 Nucleic Acids Research, 2010, Vol. 38, Database issue D563–D569 doi:10.1093/nar/gkp871 Ensembl Genomes: Extending Ensembl across the taxonomic space P. J. Kersey*, D. Lawson, E. Birney, P. S. Derwent, M. Haimel, J. Herrero, S. Keenan, A. Kerhornou, G. Koscielny, A. Ka¨ ha¨ ri, R. J. Kinsella, E. Kulesha, U. Maheswari, K. Megy, M. Nuhn, G. Proctor, D. Staines, F. Valentin, A. J. Vilella and A. Yates EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SD, UK Received August 14, 2009; Revised September 28, 2009; Accepted September 29, 2009 ABSTRACT nucleotide archives; numerous other genomes exist in states of partial assembly and annotation; thousands of Ensembl Genomes (http://www.ensemblgenomes viral genomes sequences have also been generated. .org) is a new portal offering integrated access to Moreover, the increasing use of high-throughput genome-scale data from non-vertebrate species sequencing technologies is rapidly reducing the cost of of scientific interest, developed using the Ensembl genome sequencing, leading to an accelerating rate of genome annotation and visualisation platform. data production. This not only makes it likely that in Ensembl Genomes consists of five sub-portals (for the near future, the genomes of all species of scientific bacteria, protists, fungi, plants and invertebrate interest will be sequenced; but also the genomes of many metazoa) designed to complement the availability individuals, with the possibility of providing accurate and of vertebrate genomes in Ensembl. Many of the sophisticated annotation through the similarly low-cost databases supporting the portal have been built in application of functional assays.
  • A DNA Database in the NHS: Your Freedom up for Sale?

    A DNA Database in the NHS: Your Freedom up for Sale?

    A DNA database in the NHS: Your freedom up for sale? May 2013 In April 2013, the Caldicott Committee, including Government Chief Scientist Sir Mark Walport, proposed new rules for data-sharing which would allow the Government to build a DNA database of the whole population of England in the NHS by stealth.1 The plan is to make NHS medical records and people’s genetic information available to commercial companies and to use public-private partnerships to build a system where all private information about every citizen is also accessible to the police, social workers, security services and Government. The Wellcome Trust, which was involved in the Human Genome Project and was led by Walport for ten years, has produced a plan which involves including a variant file, containing the whole genome of every person minus the reference genome, as an attachment to every medical record in the NHS in England.2 This data would be made available to ‘researchers’ (including commercial companies) for data-mining in the cloud and personalised risk assessments would be returned to individuals. The aim is to transform the NHS in line with proposals developed more than a decade ago by former GlaxoSmithKline Chairman Sir Richard Sykes. This is expected to massively expand the market for medicines, medical tests and other products, such as supplements and cholesterol-lowering margarines, by allowing products to be marketed to individuals based on personal risk assessments, created using statistical analysis of genetic data, medical records and other health information. The proposal to build a DNA database in the NHS was endorsed by the Human Genomics Strategy Group in 20123,4 and the Government (led by Prime Minister David Cameron) has quietly adopted this recommendation without telling members of the public.
  • Rare Variant Contribution to Human Disease in 281,104 UK Biobank Exomes W ­ 1,19 1,19 2,19 2 2 Quanli Wang , Ryan S

    Rare Variant Contribution to Human Disease in 281,104 UK Biobank Exomes W ­ 1,19 1,19 2,19 2 2 Quanli Wang , Ryan S

    https://doi.org/10.1038/s41586-021-03855-y Accelerated Article Preview Rare variant contribution to human disease W in 281,104 UK Biobank exomes E VI Received: 3 November 2020 Quanli Wang, Ryan S. Dhindsa, Keren Carss, Andrew R. Harper, Abhishek N ag­­, I oa nn a Tachmazidou, Dimitrios Vitsios, Sri V. V. Deevi, Alex Mackay, EDaniel Muthas, Accepted: 28 July 2021 Michael Hühn, Sue Monkley, Henric O ls so n , S eb astian Wasilewski, Katherine R. Smith, Accelerated Article Preview Published Ruth March, Adam Platt, Carolina Haefliger & Slavé PetrovskiR online 10 August 2021 P Cite this article as: Wang, Q. et al. Rare variant This is a PDF fle of a peer-reviewed paper that has been accepted for publication. contribution to human disease in 281,104 UK Biobank exomes. Nature https:// Although unedited, the content has been subjectedE to preliminary formatting. Nature doi.org/10.1038/s41586-021-03855-y (2021). is providing this early version of the typeset paper as a service to our authors and Open access readers. The text and fgures will undergoL copyediting and a proof review before the paper is published in its fnal form. Please note that during the production process errors may be discovered which Ccould afect the content, and all legal disclaimers apply. TI R A D E T A R E L E C C A Nature | www.nature.com Article Rare variant contribution to human disease in 281,104 UK Biobank exomes W 1,19 1,19 2,19 2 2 https://doi.org/10.1038/s41586-021-03855-y Quanli Wang , Ryan S.
  • The ELIXIR Core Data Resources: ​Fundamental Infrastructure for The

    The ELIXIR Core Data Resources: ​Fundamental Infrastructure for The

    Supplementary Data: The ELIXIR Core Data Resources: fundamental infrastructure ​ for the life sciences The “Supporting Material” referred to within this Supplementary Data can be found in the Supporting.Material.CDR.infrastructure file, DOI: 10.5281/zenodo.2625247 (https://zenodo.org/record/2625247). ​ ​ Figure 1. Scale of the Core Data Resources Table S1. Data from which Figure 1 is derived: Year 2013 2014 2015 2016 2017 Data entries 765881651 997794559 1726529931 1853429002 2715599247 Monthly user/IP addresses 1700660 2109586 2413724 2502617 2867265 FTEs 270 292.65 295.65 289.7 311.2 Figure 1 includes data from the following Core Data Resources: ArrayExpress, BRENDA, CATH, ChEBI, ChEMBL, EGA, ENA, Ensembl, Ensembl Genomes, EuropePMC, HPA, IntAct /MINT , InterPro, PDBe, PRIDE, SILVA, STRING, UniProt ● Note that Ensembl’s compute infrastructure physically relocated in 2016, so “Users/IP address” data are not available for that year. In this case, the 2015 numbers were rolled forward to 2016. ● Note that STRING makes only minor releases in 2014 and 2016, in that the interactions are re-computed, but the number of “Data entries” remains unchanged. The major releases that change the number of “Data entries” happened in 2013 and 2015. So, for “Data entries” , the number for 2013 was rolled forward to 2014, and the number for 2015 was rolled forward to 2016. The ELIXIR Core Data Resources: fundamental infrastructure for the life sciences ​ 1 Figure 2: Usage of Core Data Resources in research The following steps were taken: 1. API calls were run on open access full text articles in Europe PMC to identify articles that ​ ​ mention Core Data Resource by name or include specific data record accession numbers.
  • Open Targets Genetics

    Open Targets Genetics

    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.16.299271; this version posted September 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 1 Open Targets Genetics: An open approach to systematically prioritize causal variants 2 and genes at all published GWAS trait-associated loci 3 4 Edward Mountjoy1,2, Ellen M. Schmidt1,2, Miguel Carmona2,3, Gareth Peat2,3, Alfredo Miranda2,3, 5 Luca Fumis2,3, James Hayhurst2,3, Annalisa Buniello2,3, Jeremy Schwartzentruber1,2,3, Mohd 6 Anisul Karim1,2, Daniel Wright1,2, Andrew Hercules2,3, Eliseo Papa4, Eric Fauman5, Jeffrey C. 7 Barrett1,2, John A. Todd6, David Ochoa2,3, Ian Dunham1,2,3, Maya Ghoussaini1,2,*. 8 9 1. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 10 1SA, UK 11 2. Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK 12 3. European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), 13 Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK 14 4. Systems Biology, Biogen, Cambridge, MA, 02142, United States 15 5. Integrative Biology, Internal Medicine Research Unit, Pfizer Worldwide Research, 16 Development and Medical, Cambridge, MA 02139, United States 17 6. Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford 18 Biomedical Research Centre, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, 19 UK 20 * Corresponding author 21 22 23 24 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.16.299271; this version posted September 17, 2020.
  • Select Committee on Science and Technology Corrected Oral Evidence: Ageing: Science, Technology and Healthy Living

    Select Committee on Science and Technology Corrected Oral Evidence: Ageing: Science, Technology and Healthy Living

    Select Committee on Science and Technology Corrected oral evidence: Ageing: science, technology and healthy living Tuesday 25 February 2020 10.20 am Watch the meeting Members present: Lord Patel (The Chair); Lord Borwick; Lord Browne of Ladyton; Baroness Hilton of Eggardon; Lord Kakkar; Lord Mair; Baroness Manningham-Buller; Baroness Penn; Viscount Ridley; Baroness Rock; Baroness Sheehan; Baroness Walmsley; Lord Winston; Baroness Young of Old Scone. Evidence Session No. 15 Heard in Public Questions 131 - 138 Witnesses Dame Fiona Caldicott, National Data Guardian; Matthew Gould, CEO, NHSX; Chris Roebuck, Chief Statistician, NHS Digital; Dr Jem Rashbass, Executive Director of Master Registries and Data, NHS Digital. USE OF THE TRANSCRIPT This is a corrected transcript of evidence taken in public and webcast on www.parliamentlive.tv. 1 Examination of witnesses Dame Fiona Caldicott, Matthew Gould, Chris Roebuck and Dr Jem Rashbass. Q131 The Chair: Good morning, Dame Fiona and gentlemen. Welcome and thank you for coming today to help us with this inquiry. There are some familiar faces to me; it is nice to see you. Before we start, would you mind introducing yourselves for the record from my left? If you want to make an opening statement, feel free to do so. If you have any interests to declare, please do so at the beginning. Chris Roebuck: I am the chief statistician at NHS Digital. I am accountable for the nearly 300 sets of official statistics we produce each year. These cover a range of health and care data, predominantly in England, including administrative data, clinical data and survey data. We release them to encourage transparency, to help with local and national decision-making and for public accountability.
  • (DDD) Project: What a Genomic Approach Can Achieve

    (DDD) Project: What a Genomic Approach Can Achieve

    The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve RCP ADVANCED MEDICINE, LONDON FEB 5TH 2018 HELEN FIRTH DM FRCP DCH, SANGER INSTITUTE 3,000,000,000 bases in each human genome Disease & developmental Health & development disorders Fascinating facts about your genome! –~20,000 protein-coding genes –~30% of genes have a known role in disease or developmental disorders –~10,000 protein altering variants –~100 protein truncating variants –~70 de novo mutations (~1-2 coding ie. In exons of genes) Rare Disease affects 1 in 17 people •Prior to DDD, diagnostic success in patients with rare paediatric disease was poor •Not possible to diagnose many patients with current methodology in routine use– maximum benefit in this group •DDD recruited patients with severe/extreme clinical features present from early childhood with high expectation of genetic basis •Recruitment was primarily of trios (ie The Doctor Sir Luke Fildes (1887) child and both parents) ~ 90% Making a genomic diagnosis of a rare disease improves care •Accurate diagnosis is the cornerstone of good medical practice – informing management, treatment, prognosis and prevention •Enables risk to other family members to be determined enabling predictive testing with potential for surveillance and therapy in some disorders February 28th 2018 •Reduces sense of isolation, enabling better access to support and information •Curtails the diagnostic odyssey •Not just a descriptive label; identifies the fundamental cause of disease A genomic diagnosis can be a gateway to better treatment •Not just a descriptive label; identifies the fundamental cause of disease •Biallelic mutations in the CFTR gene cause Cystic Fibrosis • CFTR protein is an epithelial ion channel regulating absorption/ secretion of salt and water in the lung, sweat glands, pancreas & GI tract.
  • Cambridge University Reporter, Thursday, 1 December 2011

    Cambridge University Reporter, Thursday, 1 December 2011

    CAMBRIDGE UNIVERSITY REPORTER S PECIAL N O 4 T HUR S D AY 1 D ECEMBER 2011 VOL CXLII MEMBERS OF UNIVERSITY BODIES REPRESENTATIVES OF THE UNIVERSITY PUBLISHED BY AUTHORITY MEMBERS OF UNIVERSITY BODIES REPRESENTATIVES OF THE UNIVERSITY P ART II. M EMBER S OF U N I V ER S I T Y B ODIE S Faculty Boards and Degree Committees 18 Committees 25 Nominating and appointing bodies: Trustees, Managers, Awarders, of Funds, abbreviations 1 Scholarships, Studentships, Prizes, etc. 31 Septemviri, Court of Discipline 1 Representatives of the Colleges and Approved University Tribunal, Summary Court 1 Foundations for Election of Members of Council, Audit Committee, Finance Committee 2 the Finance Committee 47 General Board of the Faculties 2 Other Committees of the Central Bodies 2 Boards of Electors to Professorships 5 P ART III. R EPRE S E ntAT I V E S OF T HE Advisory Committees for elections to Professorships 6 U N I V ER S I T Y Boards of Electors to offices other than Professorships 7 Syndicates 7 1. Representative Governors, etc. 48 Boards 9 2. Representative Trustees 50 Councils of the Schools 11 3. Cambridge Foundation: Trustees 50 Appointments Committees 12 4. Cambridge Enterprise Ltd: Board of Directors 50 NOTICE BY THE EDITOR This issue of the Officers Number comprises a revised version of Part II and Part III and includes data received up to 14 November 2011. Part I (University Officers) will be published separately. The next issue (Parts II and III) will be published in the Lent Term 2012. NOTES (1) The mention of a year after a name or a set of names in Part II means, unless it is otherwise specified, that retirement from membership is due on 31 December of that year.
  • Different Evolutionary Patterns of Snps Between Domains and Unassigned Regions in Human Protein‑Coding Sequences

    Different Evolutionary Patterns of Snps Between Domains and Unassigned Regions in Human Protein‑Coding Sequences

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Mol Genet Genomics (2016) 291:1127–1136 DOI 10.1007/s00438-016-1170-7 ORIGINAL ARTICLE Different evolutionary patterns of SNPs between domains and unassigned regions in human protein‑coding sequences Erli Pang1 · Xiaomei Wu2 · Kui Lin1 Received: 14 September 2015 / Accepted: 18 January 2016 / Published online: 30 January 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Protein evolution plays an important role in Furthermore, the selective strength on domains is signifi- the evolution of each genome. Because of their functional cantly greater than that on unassigned regions. In addition, nature, in general, most of their parts or sites are differently among all of the human protein sequences, there are 117 constrained selectively, particularly by purifying selection. PfamA domains in which no SNPs are found. Our results Most previous studies on protein evolution considered indi- highlight an important aspect of protein domains and may vidual proteins in their entirety or compared protein-coding contribute to our understanding of protein evolution. sequences with non-coding sequences. Less attention has been paid to the evolution of different parts within each pro- Keywords Human genome · Protein-coding sequence · tein of a given genome. To this end, based on PfamA anno- Protein domain · SNPs · Natural selection tation of all human proteins, each protein sequence can be split into two parts: domains or unassigned regions. Using this rationale, single nucleotide polymorphisms (SNPs) in Introduction protein-coding sequences from the 1000 Genomes Project were mapped according to two classifications: SNPs occur- Studying protein evolution is crucial for understanding ring within protein domains and those within unassigned the evolution of speciation and adaptation, senescence and regions.
  • Annual Scientific Report 2013 on the Cover Structure 3Fof in the Protein Data Bank, Determined by Laponogov, I

    Annual Scientific Report 2013 on the Cover Structure 3Fof in the Protein Data Bank, Determined by Laponogov, I

    EMBL-European Bioinformatics Institute Annual Scientific Report 2013 On the cover Structure 3fof in the Protein Data Bank, determined by Laponogov, I. et al. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nature Structural & Molecular Biology 16, 667-669. © 2014 European Molecular Biology Laboratory This publication was produced by the External Relations team at the European Bioinformatics Institute (EMBL-EBI) A digital version of the brochure can be found at www.ebi.ac.uk/about/brochures For more information about EMBL-EBI please contact: [email protected] Contents Introduction & overview 3 Services 8 Genes, genomes and variation 8 Molecular atlas 12 Proteins and protein families 14 Molecular and cellular structures 18 Chemical biology 20 Molecular systems 22 Cross-domain tools and resources 24 Research 26 Support 32 ELIXIR 36 Facts and figures 38 Funding & resource allocation 38 Growth of core resources 40 Collaborations 42 Our staff in 2013 44 Scientific advisory committees 46 Major database collaborations 50 Publications 52 Organisation of EMBL-EBI leadership 61 2013 EMBL-EBI Annual Scientific Report 1 Foreword Welcome to EMBL-EBI’s 2013 Annual Scientific Report. Here we look back on our major achievements during the year, reflecting on the delivery of our world-class services, research, training, industry collaboration and European coordination of life-science data. The past year has been one full of exciting changes, both scientifically and organisationally. We unveiled a new website that helps users explore our resources more seamlessly, saw the publication of ground-breaking work in data storage and synthetic biology, joined the global alliance for global health, built important new relationships with our partners in industry and celebrated the launch of ELIXIR.